MedTrace Logo

Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu

NCT04279197 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2022-01-03

No results posted yet for this study

Summary

According to previous studies, viral pneumonia can develop into pulmonary fibrosis, which can affect patients'lung function and even life health.This study aims to observe the efficacy and safety of Fuzheng Huayu Tablets in the treatment of pulmonary fibrosis after COVID-19.

Conditions

  • Pulmonary Fibrosis Due to COVID-19

Interventions

DRUG

Fuzheng Huayu Tablet

FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.

DRUG

Vitamin C tablets

Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral；

DRUG

Placebo

Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.

OTHER

respiratory function rehabilitation training

Health exercise, once a day

Sponsors & Collaborators

  • Hubei Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Jingmen No.1 People's Hospital

    collaborator OTHER

  • Wuhan No.1 Hospital

    collaborator OTHER

  • Wuhan Third Hospital

    collaborator OTHER

  • Huangshi Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN

  • ShuGuang Hospital

    lead OTHER

Principal Investigators

  • Chenghai Liu · Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-23
Primary Completion
2021-03-24
Completion
2021-03-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04279197 on ClinicalTrials.gov